Angion Biomedica Overview

  • Founded

  • 1998

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 12

Employees
  • Latest Deal Type

  • M&A

  • Investors

  • 1

Angion Biomedica General Information

Description

Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Contact Information

Website
www.angion.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Elicio Therapeutics
Primary Office
  • 51 Charles Lindbergh Boulevard
  • Uniondale
  • Long Island City, NY 11553
  • United States
+1 (516) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Angion Biomedica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 01-Jun-2023 00000 Completed Generating Revenue
9. PIPE 09-Feb-2021 0000 00000 Completed Generating Revenue
8. IPO 05-Feb-2021 0000 00000 00000 Completed Generating Revenue
7. Later Stage VC 23-Jun-2020 00.00 0000 Completed Clinical Trials - Phase 3
6. Debt - PPP 09-Apr-2020 00000 000.00 Completed Clinical Trials - Phase 3
5. Later Stage VC 27-Jan-2020 00.000 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 17-Jul-2018 000.00 000.00 00000 Completed Clinical Trials - Phase 3
3. Grant 01-Jan-2017 000.00 00.000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A) 20-Feb-2015 $4.36M $4.36M 000.00 Completed Clinical Trials - Phase 3
1. IPO 24-Oct-2014 Cancelled Clinical Trials - Phase 3
To view Angion Biomedica’s complete valuation and funding history, request access »

Angion Biomedica Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000 00.000000 00000.00 00000.00 00000.00 00.000
Series A 00,000 00.000000 0000.00 0000.00 0000.00 00.000
To view Angion Biomedica’s complete cap table history, request access »

Angion Biomedica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercia
Drug Discovery
Long Island City, NY
12 As of 2022
00000
000000&0 00000

000000

rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor inc
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut l
000000000000000
South San Francisco, CA
00 As of 0000
00000
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Angion Biomedica Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akebia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
00-000000 Venture Capital-Backed Utrecht, Netherlands 00 00000 000000 - 000 00000
00000000000 Formerly PE-Backed Cary, NC 000 000.00 000000000000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 15 competitors. Get the full list »

Angion Biomedica Patents

  • 163

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 15

    Granted

  • 6

    Pending

  • 000

    Expiring in next 12 mo

Angion Biomedica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3189725-A1 Inhibitors of rho-associated coiled-coil kinase Pending 21-Jul-2020 0000000000
EP-4185579-A1 Inhibitors of rho-associated coiled-coil kinase Pending 21-Jul-2020 0000000000
EP-4175634-A1 Solid forms of (z)-methyl 3-(((4-(n-methyl-2-(4-methylpiperazin-l- yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxo-2, 3-dihydro- lh-pyrrolo[2,3-b]pyridine-6-carboxylate and salts thereof Pending 01-Jul-2020 0000000000
AU-2020386913-A1 Methods for treating inflammatory bowel disease Pending 20-Nov-2019 0000000000
CA-3159601-A1 Methods for treating inflammatory bowel disease Pending 20-Nov-2019 A61K31/437
To view Angion Biomedica’s complete patent history, request access »

Angion Biomedica Executive Team (6)

Name Title Board Seat Contact Info
Jay Venkatesan MD Chief Executive Officer, President, Board Member and Chairman
You’re viewing 1 of 6 executive team members. Get the full list »

Angion Biomedica Board Members (6)

Name Representing Role Since
Itzhak Goldberg MD Angion Biomedica Chairman & Board Member 000 0000
You’re viewing 1 of 6 board members. Get the full list »

Angion Biomedica Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Angion Biomedica Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Formic Ventures Venture Capital Minority 000 0000 000000 0
National Science Foundation Government Minority 000 0000 000000 0
SDL Ventures Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government Minority 000 0000 000000 0
To view Angion Biomedica’s complete investors history, request access »

Angion Biomedica Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 01-Jun-2023 0000000 00 Drug Discovery 000 00000
000 000000000 01-Jul-2017 000000000 Personal Products
Ohr Cosmetics 15-Nov-2013 Corporate 00000 Personal Products
To view Angion Biomedica’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial